One potential gene- and mutation-agnostic therapy for RP is knockdown of neural retina leucine zipper (Nrl) or nuclear receptor subfamily 2 group E member 3 (Nr2e3) in mature retina (11). This evidence concerns the gene NR2E3 and retinitis pigmentosa 1.